ARCUTIS BIOTHERAPEUTICS, INC.
At today's price, ARCUTIS BIOTHERAPEUTICS, INC. (ARQT) is priced for today's economics sustained for ~9.7 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
• Arcutis is a dermatology company built around one molecule, roflumilast, sold under the ZORYVE brand in several topical forms, and it generated $105.4 million in net product revenue in Q1 2026, up 65% year over year [Source: Q1 2026 results, May 2026]. • The surprising number is the gross margin: at 90.7%, ZORYVE earns software-like economics, and the company has crossed into positive operating cash flow even while still reporting a per-share loss [Source: Q1 2026 results, May 2026]. • The pri
Is ARQT overvalued? See what's priced in →
258 institutional managers reported holding ARQT in 13F filings for the quarter ended 2026-03-31. 30 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 15.8M shares were sold short as of the 2026-06-15 count, about 12% of shares outstanding (10 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ARQT's share count grew 165.8% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at ARQT over the trailing three years: 2023: 1 buy totaling $200k; 2024: 6 buys totaling $248k; 2025: 9 buys totaling $373k. 15 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ARQT's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-09 | -2.0% | -52.0% |
| 2023-11-04 | +9.9% | +52.0% |
| 2024-02-28 | +7.4% | -15.1% |
| 2024-05-15 | +15.6% | +11.2% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ARQT's latest 8-K filings: 2026-07-16 (items 5.02, 7.01, 9.01); 2026-06-09 (items 5.07, 8.01, 9.01); 2026-05-06 (items 9.01); 2026-02-25 (items 2.02, 9.01); 2025-12-08 (items 5.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.